Free Trial

Pediatrix Medical Group, Inc. (NYSE:MD) Shares Bought by Nuveen Asset Management LLC

Pediatrix Medical Group logo with Medical background

Nuveen Asset Management LLC lifted its stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 110.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 485,587 shares of the company's stock after purchasing an additional 255,273 shares during the period. Nuveen Asset Management LLC owned about 0.57% of Pediatrix Medical Group worth $6,371,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Numerai GP LLC purchased a new position in Pediatrix Medical Group in the fourth quarter valued at $214,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Pediatrix Medical Group by 6.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,002 shares of the company's stock valued at $643,000 after buying an additional 2,801 shares in the last quarter. Gotham Asset Management LLC raised its stake in Pediatrix Medical Group by 38.0% in the fourth quarter. Gotham Asset Management LLC now owns 54,642 shares of the company's stock valued at $717,000 after buying an additional 15,044 shares in the last quarter. Graham Capital Management L.P. acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at $463,000. Finally, Deutsche Bank AG raised its stake in Pediatrix Medical Group by 53.1% in the fourth quarter. Deutsche Bank AG now owns 74,023 shares of the company's stock valued at $971,000 after buying an additional 25,663 shares in the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on MD shares. Truist Financial cut their price target on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Macquarie raised their price target on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, UBS Group cut their price target on Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating on the stock in a research note on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $16.67.

Read Our Latest Research Report on MD

Pediatrix Medical Group Stock Performance

Shares of MD traded down $0.62 during midday trading on Monday, reaching $13.54. 701,755 shares of the stock were exchanged, compared to its average volume of 855,191. The business's 50-day moving average price is $13.72 and its 200 day moving average price is $14.03. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.60 and a quick ratio of 1.42. Pediatrix Medical Group, Inc. has a twelve month low of $6.62 and a twelve month high of $17.67. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.28, a PEG ratio of 1.74 and a beta of 1.26.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.08. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The business had revenue of $458.36 million for the quarter, compared to analysts' expectations of $451.44 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. The business's revenue was down 7.4% compared to the same quarter last year. On average, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

(Free Report)

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Featured Articles

Institutional Ownership by Quarter for Pediatrix Medical Group (NYSE:MD)

Should You Invest $1,000 in Pediatrix Medical Group Right Now?

Before you consider Pediatrix Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.

While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns
NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines